Beijing Tide Pharmaceutical Co. Ltd. has identified proteolysis targeting chimeras (PROTACs) comprising a cereblon E3 ubiquitin ligase binding moiety coupled to tyrosine-protein phosphatase non-receptor type 11 (PTPN11; PTP-2C; SHP-2) targeting agents through linkers reported to be useful for the treatment of cancer.
Mitsubishi Tanabe Pharma Corp. has divulged proteolysis targeting chimeras (PROTACs) comprising a cereblon E3 ubiquitin ligase (CRBN) binding moiety coupled to disease-associated protein targeting moiety through a linker reported to be useful for the treatment of cancer, inflammatory disorders, autoimmune disease, neurodegeneration and genetic disorders.
Risen (Shanghai) Pharma Eng Co. Ltd. and Risen (Suzhou) Pharma Tech Co. Ltd. have divulged proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding agents coupled to GTPase KRAS or its mutant targeting moiety through a linker reported to be useful for the treatment of cancer.
Beijing Neox Biotech Co. Ltd. has patented proteolysis targeting chimera (PROTACs) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to wee1-like protein kinase (Wee1) binding moiety through a linker reported to be useful for the treatment of cancer.
Chia Tai Tianqing Pharmaceutical Group Co. Ltd. has identified proteolysis targeting chimera (PROTAC) compounds comprising a E3 ubiquitin ligase-binding moiety coupled to RACα serine/threonine-protein kinase AKT targeting moiety through a linker reported to be useful for the treatment of prostate cancer.
Jiangsu Vcare Pharmatech Co. Ltd. has created new proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety covalently linked to estrogen receptor α (ER-α)-binding moiety through a linker. They are reported to be useful for the treatment of cancer and infections.
Hangzhou Zhongmei Huadong Pharmaceutical Co. Ltd. has synthesized proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently bonded to a GTPase KRAS (G12D mutant) targeting moiety through a linker reported to be useful for the treatment of cancer.
Hangzhou Zhongmei Huadong Pharmaceutical Co. Ltd. has described proteolysis targeting chimera (PROTACs) compounds comprising an E3 ubiquitin ligase-binding moiety covalently linked to a mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1)-targeting moiety. They are reported to be useful for the treatment of cancer.
Captor Therapeutics Inc. has disclosed proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase-binding moiety covalently linked to an induced myeloid leukemia cell differentiation protein MCL-1-targeting moiety through a linker.
Uppthera Inc. has described proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety coupled to a serine/threonine-protein kinase PLK1 (STPK13) targeting moiety through a linker. They are reported to be useful for the treatment of cancer and neurological disorders.
